121 related articles for article (PubMed ID: 31748757)
1. Expression of CDX2 in metastatic prostate cancer.
Guerrieri C; Jobbagy Z; Hudacko R
Pathologica; 2019 Sep; 111(3):105-107. PubMed ID: 31748757
[TBL] [Abstract][Full Text] [Related]
2. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
3. The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma.
Abouelkhair MB; Mabrouk SH; Zaki SSA; Nada OH; Hakim SA
J Gastrointest Cancer; 2021 Sep; 52(3):960-969. PubMed ID: 32929682
[TBL] [Abstract][Full Text] [Related]
4. LI-cadherin and CDX2: Useful Markers in Metastatic Gastrointestinal Adenocarcinoma Cells in Serous Cavity Effusion.
Ma H; Yu J; Tang J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):e75-e80. PubMed ID: 30095466
[TBL] [Abstract][Full Text] [Related]
5. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
Herawi M; De Marzo AM; Kristiansen G; Epstein JI
Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
[TBL] [Abstract][Full Text] [Related]
6. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
7. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
8. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
9. Expression of CDX2 and Thyroid Transcription Factor-1 in Oropharyngeal Undifferentiated Carcinomas: A Potential Diagnostic Pitfall.
Chernock RD; Bibbey S; El-Mofty SK; Carpenter DH; Lewis JS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):268-273. PubMed ID: 27389559
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Expression of CDX2 and SATB2 in Primary Breast Carcinomas.
Assarzadegan N; Gonzalo DH; Leon ME; Asirvatham JR
Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):e53. PubMed ID: 30741745
[No Abstract] [Full Text] [Related]
11. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
13. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
Altree-Tacha D; Tyrrell J; Haas T
Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907
[TBL] [Abstract][Full Text] [Related]
14. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
15. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
17. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
18. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
19. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
Strickland-Marmol LB; Khoor A; Livingston SK; Rojiani A
Arch Pathol Lab Med; 2007 Nov; 131(11):1686-90. PubMed ID: 17979487
[TBL] [Abstract][Full Text] [Related]
20. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
